Published in Medical Letter on the CDC and FDA, December 26th, 2004
Once-daily Vesicareis a global product of Yamanouchi, and this approval follows the one obtained in Europe where the product was launched in August.
Yamanouchi is constructing a marketing system of its own in the U.S. Vesicare will be marketed by its wholly owned US subsidiary, Yamanouchi Pharma America, Inc (YPA) as the first product Yamanouchi will independently market in the U.S....
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.